Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026

Beam Therapeutics (NASDAQ: BEAM) executives and clinical collaborators presented updated top-line data from the company's ongoing Phase I/II study of BEAM-302, an in vivo base-editing therapy being evaluated in patients with alpha-1 antitrypsin deficiency (AATD). The call focused on efficacy and safety results from 29 treated patients as of a February 10, 2026 data cutoff, along